Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report

Adrienn N Bourkas; Cathryn Sibbald

doi:10.1177/2050313X221138452

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report

SAGE Open Med Case Rep. 2022 Nov 28:10:2050313X221138452. doi: 10.1177/2050313X221138452. eCollection 2022.

Authors

Adrienn N Bourkas^{1

2}, Cathryn Sibbald^{2

3}

Affiliations

¹ School of Medicine, Queen's University, Kingston, ON, Canada.
² Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
³ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Abstract

This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal response to topical corticosteroids and spironolactone, improvements in hair growth on the scalp and body were noted after only 6 weeks of upadacitinib treatment.

Keywords: Alopecia areata; Janus kinase inhibitors; atopic dermatitis; hair diseases; skin diseases.

Publication types

Case Reports